Core Viewpoint - Izotropic Corporation held its Annual General and Special Meeting on December 29, 2025, where key corporate matters were approved by shareholders [1][2]. Group 1: Meeting Outcomes - All nominees for the board of directors were approved, maintaining the number of directors at five [3]. - The re-appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP was approved [3]. - An amendment to the Company's By-Laws was made to reduce the quorum requirement from 20% to at least 1% of the issued voting shares, while decisions will still require majority approval. This change addresses challenges faced by public companies, such as mail delays and disruptions in receiving voting packages [3]. Group 2: Shareholder Engagement - The Company expressed gratitude to all shareholders for their participation and ongoing support [4]. Group 3: Company Information - Izotropic Corporation focuses on innovative medical technologies and imaging products for breast cancer screening, diagnosis, and treatment [1]. - Additional information about the Company can be found on its corporate website and educational platform [5].

Core Insights - Izotropic Corporation is focused on commercializing innovative technologies for breast cancer screening, diagnosis, and treatment, with a flagship product called IzoView, a dedicated breast CT platform [1][2] - The CEO, Bob Thast, discusses the company's vision, the unique features of IzoView, and its differentiation in the breast-imaging market [2] - Planned use of proceeds over the next 12-18 months includes funding for three devices, a U.S. FDA clinical study, a partner device in the U.K., and two additional devices for CE-mark markets [2] Company Overview - Izotropic Corporation operates in the medical device sector, specifically targeting breast cancer imaging technologies [1] - The company has an exclusive CADx patent for breast CT, which is expected to contribute to future recurring revenues beyond device sales [2] Regulatory and Market Strategy - The company is initiating CE-mark activities and aims to build data to accelerate regulatory pathways and time-to-market for its devices [2] - Key regulatory, clinical, and market risks are acknowledged, along with strategies for mitigation as the company moves into 2026 [2]

Core Insights - Izotropic Corporation is gaining visibility in the expanding AI market, particularly in healthcare, with its innovative imaging technologies for breast cancer screening and treatment [1][5]. Industry Trends - The application of artificial intelligence is shifting from broad models to specialized systems that address specific industry problems, creating measurable value in sectors like healthcare, enterprise software, defense, and industrial automation [3][4]. - There is a growing trend towards the adoption of targeted AI solutions that improve performance and streamline operations, which are already being utilized in production environments [4]. Company Positioning - Companies developing targeted AI solutions are becoming increasingly relevant, as their technologies are often integrated into existing workflows, making them difficult to replace and positioning them as long-term infrastructure in their markets [5]. - Izotropic Corporation, with its IzoView technology nearing commercialization, is positioned as a unique early-stage medtech opportunity that could set a new standard in breast cancer imaging and provide significant long-term value [5].

Core Viewpoint - Izotropic Corporation is initiating a non-brokered private placement to raise up to $300,000 through the sale of 1,200,000 units at $0.25 each, with each unit comprising one common share and one transferable warrant [1][2] Group 1: Private Placement Details - The offering will consist of up to 1,200,000 units priced at $0.25 each, aiming for gross proceeds of up to $300,000 [1] - Each unit includes one common share and one warrant, allowing the holder to purchase an additional share at $0.50 for three years [1] - Proceeds from the offering will be allocated for general working capital [2] Group 2: Warrant Extension - The company has extended the expiry date of 2,841,325 outstanding share purchase warrants from September 20, 2025, to September 20, 2026, while maintaining the exercise price at $0.50 [4] - The extension is subject to final approval from the Canadian Securities Exchange (CSE) [5] Group 3: Regulatory Compliance - All securities issued in the offering will be subject to a statutory hold period of four months and one day [2] - The securities will not be registered under the United States Securities Act of 1933, and cannot be offered or sold in the U.S. without registration or an exemption [3]

Core Insights - Izotropic Corporation has launched a new podcast series titled "Beyond the Mammogram: Rethinking the Future of Breast Imaging" to engage global audiences on innovations in breast imaging [1][2] - The podcast aims to address clinical challenges and market dynamics in breast cancer detection, emphasizing the need for advanced imaging technologies [2][3] Company Initiatives - The first episode discusses the limitations of current imaging tools, particularly for women with dense breast tissue, who make up about 50% of the population [3] - With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the podcast underscores the urgent need for improved imaging technologies [3] - The podcast serves as a new communication platform to educate patients, healthcare professionals, and stakeholders about breast health [5] Product Focus - The podcast highlights Izotropic's flagship product, IzoView, which is a dedicated Breast CT Imaging System [4] - The company intends to use the podcast to build awareness as it advances IzoView toward regulatory approval and market launch [5] Accessibility and Engagement - The podcast is available in multiple languages, including English, Arabic, Chinese, French, German, Italian, and Spanish, to reach a broader audience [1] - Episode 1 is accessible on the company's YouTube channel, with future episodes planned to cover various topics related to breast imaging and patient advocacy [6]